Índice

• • ·CME: Sponsorship/Conference participants

    Página :v

    
• • ·Overview consensus statement

    Página :1-4

    Peter R Carroll, William R Fair, Gary D Grossfeld, Warren D.W Heston, Ronald Lieberman, S.Bruce Malkowicz, Hans J Stricker, John Sylvester, Donna M Peehl, François Meyer, Carol Hart

    Esquema Esquema
• • ·Is the flare phenomenon clinically significant?

    Página :5-9

    Glenn J Bubley

    Resumen Resumen Esquema Esquema
• • ·Discussion following Dr. Glenn J. Bubley’s presentation

    Página :9

    
• • ·Luteinizing hormone–releasing hormone monotherapy: a viable option for treatment of prostate cancer?

    Página :10-15

    Paul F Schellhammer

    Resumen Resumen Esquema Esquema
• • ·Discussion following Dr. William R. Fair’s presentation of Dr. Paul F. Schellhammer’s paper

    Página :15

    
• • ·Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer

    Página :16-22

    Geert J.C.M Kolvenbag, Peter Iversen, Don W.W Newling

    Resumen Resumen Esquema Esquema  
• • ·Discussion following dr. Geert J.C.M. Kolvenbag’S presentation

    Página :23

    
• • ·Luteinizing hormone–releasing hormone antagonists in prostate cancer

    Página :24-27

    Hans J Stricker

    Resumen Resumen Esquema Esquema
• • ·Discussion following Dr. Hans J. Stricker’s presentations

    Página :27

    
• • ·In vitro mechanism of PC spes

    Página :28-35

    Sophie Chenn

    Resumen Resumen Esquema Esquema  
• • ·The effects of phytotherapeutic agents on prostate cancer: an overview of recent clinical trials of PC spes

    Página :36-38

    John F. Pirani

    Resumen Resumen
• • ·Discussion following Dr. Sophie Chen’s (pages 28–35) and Dr. John F. Pirani’s presentations

    Página :38

    
• • ·Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer

    Página :39-48

    Martin E Gleave, Hideaki Miyake, Toby Zellweger, Kim Chi, Laura July, Colleen Nelson, Paul Rennie

    Resumen Resumen Esquema Esquema  
• • ·Discussion following Dr. Martin E. Gleave’s presentation

    Página :48-49

    
• • ·Early versus late androgen deprivation therapy in metastatic disease

    Página :50-55

    Don W.W Newling

    Resumen Resumen Esquema Esquema  
• • ·Discussion following DR. Don W. W. Newling’s presentation

    Página :55

    
• • ·Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy

    Página :56-64

    Gary D Grossfeld, Eric J Small, Deborah P Lubeck, David Latini, Jeanette M Broering, Peter R Carroll

    Resumen Resumen Esquema Esquema
• • ·Discussion following Dr. Gary D. Grossfeild's presentation

    Página :64

    
• • ·The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: a survey of practice patterns of urologists and radiation oncologists in the United States

    Página :65-70

    John Sylvester, Peter Grimm, John Blasco, Robert Meier, James Spiegel, Charles Heaney, William Cavanagh

    Resumen Resumen Esquema Esquema  
• • ·Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer

    Página :71-77

    François Meyer, Isabelle Bairati, Caroline Bédard, Louis Lacombe, Bernard Têtu, Yves Fradet

    Resumen Resumen Esquema Esquema  
• • ·Discussion following Dr. François Meyer’s presentation

    Página :77

    
• • ·Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer

    Página :78-82

    Anthony D’Amico

    Resumen Resumen Esquema Esquema  
• • ·Discussion following Dr. Anthony D’Amico’s presentation

    Página :82

    
• • ·Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development

    Página :83-90

    Ronald Lieberman

    Resumen Resumen Esquema Esquema  
• • ·Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia

    Página :91-93

    David G Bostwick, Junqi Qian

    Resumen Resumen Esquema Esquema
• • ·The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer

    Página :94-99

    Deborah P Lubeck, Gary D Grossfeld, Peter R Carroll

    Resumen Resumen Esquema Esquema
• • ·Discussion following Dr. Deborah P. Lubeck’s presentation

    Página :99-100

    
• • ·Osteoporosis due to androgen deprivation therapy in men with prostate cancer

    Página :101-106

    Harry W Daniell

    Resumen Resumen Esquema Esquema  
• • ·Discussion following Dr. Harry W. Daniell’s presentation

    Página :106-107

    
• • ·The role of diethylstilbestrol in the treatment of prostate cancer

    Página :108-113

    S.Bruce Malkowicz

    Resumen Resumen Esquema Esquema
• • ·Discussion following Dr. S. Bruce Malkowicz’s presentation

    Página :113

    
• • ·Growth factors and their receptors: new targets for prostate cancer therapy

    Página :114-122

    Jeremy Barton, George Blackledge, Alan Wakeling

    Resumen Resumen Esquema Esquema  
• • ·Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer

    Página :123-126

    Donna M Peehl, Eugene Seto, David Feldman

    Resumen Resumen Esquema Esquema  
• • ·The role of cyclooxygenase-2 in prostate cancer

    Página :127-131

    Alexander Kirschenbaum, Xin-Hua Liu, Shen Yao, Alice C Levine

    Resumen Resumen Esquema Esquema  
• • ·In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy

    Página :132-139

    Atsushi Uchida, Denise S O’Keefe, Dean J Bacich, Peter L Molloy, Warren D.W Heston

    Resumen Resumen Esquema Esquema  
• • ·CME: Title/Test/Answer

    Página :141-146